AACR-NCI-EORTC – Talk Bio

Actionable Insights Powered by AI

BridgeBio Oncology Therapeutics: Recent News Overview (November 2025)

3 weeks ago talkbio0Tagged AACR-NCI-EORTC, BridgeBio Oncology Therapeutics, clinical-stage biopharma, de-SPAC transaction, financial results, financing characteristics, Helix Acquisition Corp II, PI3Kδ, Piperine Extract (Standardized), ras Oncogene, third quarter 2025

BridgeBio Oncology Therapeutics; Helix Acquisition Corp II; de-SPAC transaction; PIPE financing; RAS and PI3Kα; clinical-stage biopharma; AACR-NCI-EORTC Conference; third quarter 2025 financial results

Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago talkbio0Tagged AACR-NCI-EORTC, ARID1A mutation, Clinical Trials, Edison Oncology, Molecular Targets, Orotecan, ovarian neoplasm, OXPHOS pathway, Phase 1 - 2a, VAL-413

Edison Oncology; 2025 AACR-NCI-EORTC; Molecular Targets; Cancer Therapeutics; VAL-413; Orotecan; EO3001; ARID1A mutation; ovarian cancer; Phase 1-2a clinical trial; OXPHOS pathway